# Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

Study · id `cardio:ct-nct06014112` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06014112](<https://clinicaltrials.gov/study/NCT06014112>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06014112

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 850 participants.

## Technical summary

Registry record NCT06014112. Allocation not applicable; no masking; primary purpose prevention. Start 2023-11-06 (actual); primary completion 2028-05-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 850 participants (planned count; ClinicalTrials.gov record NCT06014112, source copy `cardio:ctgov-nct06014112-2026-06-12`, retrieved 2026-11-18)
- Started: 2023-11-06 (actual) (ClinicalTrials.gov record NCT06014112, source copy `cardio:ctgov-nct06014112-2026-06-12`, retrieved 2026-11-18)
- Primary completion: 2028-05-06 (anticipated) (ClinicalTrials.gov record NCT06014112, source copy `cardio:ctgov-nct06014112-2026-06-12`, retrieved 2026-11-18)
- Completion: 2028-05-06 (anticipated) (ClinicalTrials.gov record NCT06014112, source copy `cardio:ctgov-nct06014112-2026-06-12`, retrieved 2026-11-18)
- Countries: France (ClinicalTrials.gov record NCT06014112, source copy `cardio:ctgov-nct06014112-2026-06-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06014112-2026-06-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS
- Acronym: FREESCA
- Condition: Acute Coronary Syndrome
- Condition: Continuous Glucose Measurement
- Condition: Glycemic Variability
- Condition: Cardiovascular Event
- Intervention (Device): Freestyle Libre Pro iQ
- Lead sponsor: University Hospital, Montpellier
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: University Hospital, Montpellier (`cardio:org-university-hospital-montpellier`)

## Provenance

Content hash: 86ee420fc740763494a7572583f4494f895830a26a1391a6da60d45b56429e5a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
